BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $102 | -100.0% | 7,365 | -50.0% | 0.07% | -95.4% |
| Q3 2022 | $2,227,000 | +1.9% | 14,730 | -1.8% | 1.57% | -1.4% |
| Q2 2022 | $2,186,000 | +31.7% | 15,000 | +7.1% | 1.59% | +33.1% |
| Q1 2022 | $1,660,000 | +0.4% | 14,000 | +16.7% | 1.20% | +12.0% |
| Q4 2021 | $1,654,000 | +19.1% | 12,000 | +20.0% | 1.07% | +12.9% |
| Q3 2021 | $1,389,000 | +43.0% | 10,000 | 0.0% | 0.94% | +62.7% |
| Q2 2021 | $971,000 | +42.0% | 10,000 | 0.0% | 0.58% | +43.1% |
| Q1 2021 | $684,000 | -20.2% | 10,000 | 0.0% | 0.41% | -17.8% |
| Q4 2020 | $857,000 | -34.1% | 10,000 | -50.0% | 0.49% | +13.8% |
| Q3 2020 | $1,300,000 | +77.8% | 20,000 | +100.0% | 0.43% | -1.8% |
| Q2 2020 | $731,000 | +115.0% | 10,000 | 0.0% | 0.44% | +46.4% |
| Q1 2020 | $340,000 | -37.5% | 10,000 | 0.0% | 0.30% | -23.5% |
| Q4 2019 | $544,000 | – | 10,000 | – | 0.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |